Cargando…

Drug Triggers and Clinic of Acute Generalized Exanthematous Pustulosis (AGEP): A Literature Case Series of 297 Patients

Acute generalized exanthematous pustulosis (AGEP) is a rare skin reaction, commonly caused by drugs. Available evidence mostly relies on small studies or case reports. We collected published AGEP case reports and, subsequently, described the patient characteristics, suspect and concomitant drugs, ti...

Descripción completa

Detalles Bibliográficos
Autores principales: Vallejo-Yagüe, Enriqueta, Martinez-De la Torre, Adrian, Mohamad, Omar S., Sabu, Shweta, Burden, Andrea M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8780223/
https://www.ncbi.nlm.nih.gov/pubmed/35054090
http://dx.doi.org/10.3390/jcm11020397
_version_ 1784637784615550976
author Vallejo-Yagüe, Enriqueta
Martinez-De la Torre, Adrian
Mohamad, Omar S.
Sabu, Shweta
Burden, Andrea M.
author_facet Vallejo-Yagüe, Enriqueta
Martinez-De la Torre, Adrian
Mohamad, Omar S.
Sabu, Shweta
Burden, Andrea M.
author_sort Vallejo-Yagüe, Enriqueta
collection PubMed
description Acute generalized exanthematous pustulosis (AGEP) is a rare skin reaction, commonly caused by drugs. Available evidence mostly relies on small studies or case reports. We collected published AGEP case reports and, subsequently, described the patient characteristics, suspect and concomitant drugs, time to onset, disease management, and clinical prognosis. This study included 297 AGEP patients (64.3% women) obtained from 250 published case reports or case series with individual patient data. AGEP affected patients of all ages, but the majority of patients (88.2%) were ≥25 years old. The most frequently reported suspect drugs were anti-infectives for systemic use (36.5%), particularly antibacterials for systemic use (31.0%), and especially beta-lactam antibacterials (18.3%) and macrolides (4.3%). Other frequent suspect drugs were antineoplastics (12.2%), and anti-inflammatory/anti-rheumatic products (5.2%) plus hydroxychloroquine (12.8%). Mean time to onset was 9.1 days (standard deviation SD 13.94). Some patients developed fever (64.3%) and systemic involvement (18.9%), and most patients (76.4%) received pharmacological treatment for AGEP. Seven patients died, although five of them were already critically ill prior to AGEP. In conclusion, antibiotics remain the most common suspected cause of AGEP. While case mortality rate may be up to 2.5%, disentangling the role of AGEP on the fatal outcome from the role of the preexisting health conditions remains challenging.
format Online
Article
Text
id pubmed-8780223
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-87802232022-01-22 Drug Triggers and Clinic of Acute Generalized Exanthematous Pustulosis (AGEP): A Literature Case Series of 297 Patients Vallejo-Yagüe, Enriqueta Martinez-De la Torre, Adrian Mohamad, Omar S. Sabu, Shweta Burden, Andrea M. J Clin Med Review Acute generalized exanthematous pustulosis (AGEP) is a rare skin reaction, commonly caused by drugs. Available evidence mostly relies on small studies or case reports. We collected published AGEP case reports and, subsequently, described the patient characteristics, suspect and concomitant drugs, time to onset, disease management, and clinical prognosis. This study included 297 AGEP patients (64.3% women) obtained from 250 published case reports or case series with individual patient data. AGEP affected patients of all ages, but the majority of patients (88.2%) were ≥25 years old. The most frequently reported suspect drugs were anti-infectives for systemic use (36.5%), particularly antibacterials for systemic use (31.0%), and especially beta-lactam antibacterials (18.3%) and macrolides (4.3%). Other frequent suspect drugs were antineoplastics (12.2%), and anti-inflammatory/anti-rheumatic products (5.2%) plus hydroxychloroquine (12.8%). Mean time to onset was 9.1 days (standard deviation SD 13.94). Some patients developed fever (64.3%) and systemic involvement (18.9%), and most patients (76.4%) received pharmacological treatment for AGEP. Seven patients died, although five of them were already critically ill prior to AGEP. In conclusion, antibiotics remain the most common suspected cause of AGEP. While case mortality rate may be up to 2.5%, disentangling the role of AGEP on the fatal outcome from the role of the preexisting health conditions remains challenging. MDPI 2022-01-13 /pmc/articles/PMC8780223/ /pubmed/35054090 http://dx.doi.org/10.3390/jcm11020397 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Vallejo-Yagüe, Enriqueta
Martinez-De la Torre, Adrian
Mohamad, Omar S.
Sabu, Shweta
Burden, Andrea M.
Drug Triggers and Clinic of Acute Generalized Exanthematous Pustulosis (AGEP): A Literature Case Series of 297 Patients
title Drug Triggers and Clinic of Acute Generalized Exanthematous Pustulosis (AGEP): A Literature Case Series of 297 Patients
title_full Drug Triggers and Clinic of Acute Generalized Exanthematous Pustulosis (AGEP): A Literature Case Series of 297 Patients
title_fullStr Drug Triggers and Clinic of Acute Generalized Exanthematous Pustulosis (AGEP): A Literature Case Series of 297 Patients
title_full_unstemmed Drug Triggers and Clinic of Acute Generalized Exanthematous Pustulosis (AGEP): A Literature Case Series of 297 Patients
title_short Drug Triggers and Clinic of Acute Generalized Exanthematous Pustulosis (AGEP): A Literature Case Series of 297 Patients
title_sort drug triggers and clinic of acute generalized exanthematous pustulosis (agep): a literature case series of 297 patients
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8780223/
https://www.ncbi.nlm.nih.gov/pubmed/35054090
http://dx.doi.org/10.3390/jcm11020397
work_keys_str_mv AT vallejoyagueenriqueta drugtriggersandclinicofacutegeneralizedexanthematouspustulosisagepaliteraturecaseseriesof297patients
AT martinezdelatorreadrian drugtriggersandclinicofacutegeneralizedexanthematouspustulosisagepaliteraturecaseseriesof297patients
AT mohamadomars drugtriggersandclinicofacutegeneralizedexanthematouspustulosisagepaliteraturecaseseriesof297patients
AT sabushweta drugtriggersandclinicofacutegeneralizedexanthematouspustulosisagepaliteraturecaseseriesof297patients
AT burdenandream drugtriggersandclinicofacutegeneralizedexanthematouspustulosisagepaliteraturecaseseriesof297patients